- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
- Verve Therapeutics Announces Leadership Update
- Verve Therapeutics to Participate in Upcoming Investor Conferences
- Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
- Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Updates on its PCSK9 Program
- Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
- Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
More ▼
Key statistics
On Wednesday, Verve Therapeutics Inc (VERV:NSQ) closed at 5.14, 12.10% above the 52 week low of 4.59 set on Jun 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.00 |
---|---|
High | 5.37 |
Low | 5.00 |
Bid | 5.10 |
Offer | 5.25 |
Previous close | 5.00 |
Average volume | 1.69m |
---|---|
Shares outstanding | 83.97m |
Free float | 77.50m |
P/E (TTM) | -- |
Market cap | 419.83m USD |
EPS (TTM) | -2.87 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼